Browse the evidence

For trials with mean baseline BMI <25, LDL cholesterol increased by 41 mg/dL on a low-carbohydrate diet.

Practitioners should be aware that low-carbohydrate diets may significantly raise LDL cholesterol in individuals with low BMI.

Preoperative discontinuation of semaglutide for > 21 days results in RGC similar to non-semaglutide users.

Practitioners should advise patients to discontinue semaglutide well in advance of procedures to reduce RGC risk.

The presence of ongoing digestive symptoms is significantly associated with increased RGC in semaglutide users.

Clinicians should monitor digestive symptoms in patients using semaglutide to assess RGC risk.

GLP-1 RA use was associated with lower medication use (RR, 0.53; 95% CI, 0.46-0.61; P < .001).

GLP-1 RAs may reduce the need for other medications in IIH management.

GLP-1 RA use was associated with reduced headaches (RR, 0.45; 95% CI, 0.35-0.58; P < .001).

GLP-1 RAs may help alleviate headache symptoms in IIH patients.

GLP-1 RA therapy is associated with significant reductions in procedural interventions (RR, 0.44; 95% CI, 0.30-0.63; P < .001).

GLP-1 RAs may reduce the need for surgical or other procedural interventions in IIH management.

Tirzepatide treatment results in an unprecedented improvement of glycaemic control and lowering of body weight.

Tirzepatide may be an effective treatment option for improving blood sugar levels and reducing weight in patients with type 2 diabetes.

High total carbohydrate intake is associated with high CVD morbidity (RR 1.08, 95% CI 1.02-1.13).

Limiting carbohydrate intake may help reduce the risk of cardiovascular disease.

High total fat intake is associated with a decreased all-cause mortality risk (RR 0.92, 95% CI 0.85-0.99).

Incorporating healthy fats into the diet may lower the risk of all-cause mortality.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduced the risk of any cardiovascular event in overweight or obese adults without diabetes.

GLP-1 RA can be considered for reducing cardiovascular risk in overweight or obese patients without diabetes.

In the study, 8.7% of participants receiving GLP-1 RA had a cardiovascular event compared to 11.2% of those receiving placebo.

The data indicates a lower incidence of cardiovascular events with GLP-1 RA treatment.

Protein consumption stimulates MPS in both prostate cancer patients on ADT and age-matched controls, but to a greater extent in controls.

Protein supplementation can enhance muscle protein synthesis, particularly in non-ADT individuals.

Bariatric surgery is currently the most effective long-term treatment for morbid obesity and type-2 diabetes mellitus.

Practitioners should consider bariatric surgery as a primary treatment option for patients with morbid obesity and type-2 diabetes.

Low energy flux may make it difficult for weight-reduced individuals to maintain energy balance.

Understanding the challenges of low energy flux can help practitioners develop better strategies for weight maintenance.

Moderate increases in physical activity following weight loss may elevate energy flux and improve appetite regulation.

Encouraging moderate physical activity can help clients manage their appetite and maintain weight loss.

Engagement and self-monitoring were highest in the Hybrid program.

Practitioners should focus on enhancing engagement strategies in weight loss programs for this demographic.

There was a trend in the whole egg group for having a greater change in lean body mass compared with that of the egg white group.

While not statistically significant, there may be a trend suggesting whole eggs could support lean mass gains better than egg whites.

Insulin resistance is associated with inactivity, ageing, genetic predisposition, and environmental factors.

Recognizing these factors can help in developing prevention strategies for insulin resistance.

GLP-1 RA treatment was associated with a significantly lower risk of all-cause mortality (hazard ratio 0.23; 95% confidence interval 0.15-0.34).

GLP-1 RAs may significantly reduce the risk of death in obese individuals without T2D.

GLP-1 RAs were associated with a lower risk of several cardiovascular complications, including ischaemic heart disease, heart failure, arrhythmias, hypertension, stroke, and atrial fibrillation.

GLP-1 RAs may help reduce the risk of serious cardiovascular issues in obese patients without T2D.

>10% weight loss is associated with cardiovascular mortality (HR, 2.76; 95% CI, 1.87-4.09) in patients with type 2 diabetes.

>10% weight loss in patients with type 2 diabetes may indicate a higher risk of cardiovascular mortality.

Unintentional weight loss in patients with type 2 diabetes may be a warning sign of poor health.

Practitioners should investigate unintentional weight loss in patients with type 2 diabetes for potential health issues.

Injectable subcutaneous medications like semaglutide are gaining popularity for weight loss.

Practitioners should be aware of the increasing use of these medications for weight loss.

A high body mass index is one of the strongest risk factors for new-onset chronic kidney disease (CKD).

Weight management should be emphasized to reduce CKD risk.